Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

The companies have not published the trial data but said in a news release that the experimental treatment extended the time ...

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush.

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Pharmaceutical giants Moderna and Merck say an experimental vaccine treatment for melanoma has shown signs of preventing the ...

Merck and Moderna say the experimental treatment extended the time before skin cancer returned in patients at high risk.

RBC Capital Markets analyst Trung Huynh downgrades shares of the Keytruda maker following a nearly 13% rally.

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...